Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLA1601 Zika vaccine safety and immunogenicity study
NCT06334393Phase 1Completed
- Sponsor
- Valneva
- Start
- Mar 2024
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VLA1601 in Zika virus infection, sponsored by Valneva. Primary endpoints: Solicited Adverse Events and Neutralizing antibodies against ZIKA virus (ZIKV) at Day 57. Started Mar 2024; status: completed.
02
Drugs
VLA1601
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT06334393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06334393.